Search Results

NANOBIOTIX announced today that Company management will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference. Please see below for details of the event.

NANOBIOTIX provided an update on operational progress and reported financial results for the first quarter of 2024.

NANOBIOTIX announced that it will report its financial and operational results for the first quarter of 2024 on May 22, 2024, before the US and EU markets open.

NANOBIOTIX announced updates to its corporate strategy designed to enable long-term growth in view of significant progress in the Company’s collaboration for the co-development and global commercialization of lead therapeutic candidate NBTXR3.

NANOBIOTIX announced that Company management will participate in fireside chats at the upcoming Guggenheim Healthy Altitudes Summit and the Leerink Partners Global Biopharma Conference.

NANOBIOTIX announced that it will report its financial and operational results for the fourth quarter and full year ended December 31, 2023, on Wednesday, April 24, 2024, after the close of the US market.

NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will host a virtual KOL (Key Opinion Leader) event Tuesday June 18, 2024 at 9:00-10:30AM EDT / 3:00-4:30PM CEST.

NANOBIOTIX provided an update on operational progress and reported financial results for the year ended December 31, 2023, and announced the filing of its universal registration document for the financial year ended December 31, 2023 with the French financial market authority, as well as of the Annual Report on Form 20-F for the financial year ended December 31, 2023 with the U.S. Securities and Exchange Commission.